These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23027660)

  • 1. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.
    Lingg N; Zhang P; Song Z; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1462-72. PubMed ID: 22829536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological significance of glycosylation in therapeutic proteins.
    Li H; d'Anjou M
    Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new large-scale manufacturing platform for complex biopharmaceuticals.
    Vogel JH; Nguyen H; Giovannini R; Ignowski J; Garger S; Salgotra A; Tom J
    Biotechnol Bioeng; 2012 Dec; 109(12):3049-58. PubMed ID: 22688835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA; Schellekens H
    Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian cell protein expression for biopharmaceutical production.
    Zhu J
    Biotechnol Adv; 2012; 30(5):1158-70. PubMed ID: 21968146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of glycosylation analysis in development of biopharmaceuticals.
    Kawasaki N; Itoh S; Hashii N; Takakura D; Qin Y; Huang X; Yamaguchi T
    Biol Pharm Bull; 2009 May; 32(5):796-800. PubMed ID: 19420744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.
    Eon-Duval A; Broly H; Gleixner R
    Biotechnol Prog; 2012; 28(3):608-22. PubMed ID: 22473974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of recombinant vaccines and antibodies in plants.
    Ko K
    Monoclon Antib Immunodiagn Immunother; 2014 Jun; 33(3):192-8. PubMed ID: 24937251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large scale production of recombinant human lactoferrin in the milk of transgenic cows.
    van Berkel PH; Welling MM; Geerts M; van Veen HA; Ravensbergen B; Salaheddine M; Pauwels EK; Pieper F; Nuijens JH; Nibbering PH
    Nat Biotechnol; 2002 May; 20(5):484-7. PubMed ID: 11981562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes.
    Sharma B
    Biotechnol Adv; 2007; 25(3):325-31. PubMed ID: 17337334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Immunogenicity of Biopharmaceuticals.
    Pineda C; Castañeda Hernández G; Jacobs IA; Alvarez DF; Carini C
    BioDrugs; 2016 Jun; 30(3):195-206. PubMed ID: 27097915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How to optimize biopharmaceutical treatment safety?].
    Prugnaud JL
    Bull Acad Natl Med; 2011 Mar; 195(3):679-95; discussion 695-8. PubMed ID: 22292313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-based production of biopharmaceuticals.
    Fischer R; Stoger E; Schillberg S; Christou P; Twyman RM
    Curr Opin Plant Biol; 2004 Apr; 7(2):152-8. PubMed ID: 15003215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of product-related factors on immunogenicity of biotherapeutics.
    Singh SK
    J Pharm Sci; 2011 Feb; 100(2):354-87. PubMed ID: 20740683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.